Bachem (OTCMKTS:BCHMF) Trading Up 29.5% – Here’s What Happened

Bachem Holding AG (OTCMKTS:BCHMF)’s share price traded up 29.5% on Thursday . The company traded as high as $82.73 and last traded at $82.73. 100 shares were traded during trading, an increase of 0% from the average session volume of 100 shares. The stock had previously closed at $63.87.

Analyst Ratings Changes

Several brokerages have commented on BCHMF. UBS Group upgraded shares of Bachem to a “buy” rating in a research report on Tuesday, December 2nd. Deutsche Bank Aktiengesellschaft upgraded Bachem to a “buy” rating in a research note on Monday, October 27th. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Bachem currently has an average rating of “Hold”.

Bachem Price Performance

The company’s 50 day moving average is $62.80 and its 200 day moving average is $64.14.

Bachem Company Profile

Bachem Holding AG is a Switzerland‐based specialty biochemical company focused on the development, manufacturing and commercialization of peptides and oligonucleotides. Serving pharmaceutical and biotechnology clients as well as academic research institutions, the company offers a broad spectrum of products ranging from custom peptide synthesis for research applications to clinical and commercial‐grade active pharmaceutical ingredients (APIs). Bachem’s expertise extends to process development, scale‐up and GMP‐compliant production, supporting projects in therapeutic areas such as oncology, metabolic disorders and infectious diseases.

Founded in 1971 and headquartered in Bubendorf, Switzerland, Bachem has grown through strategic investments in production capacity and the acquisition of complementary peptide and oligonucleotide technologies.